Anixa Biosciences (ANIX) 2024 Sidoti Virtual Micro-Cap Conference summary

Corporate overview and strategy

• Transitioned from electronics to biotech in 2017, now operates as a lean, partnership-driven startup.

• Maintains a robust pipeline with two clinical-stage programs and several preclinical assets.

• Focuses on large cancer markets: breast, ovarian, lung, prostate, and colon.

• Operates with low overhead by leveraging academic partnerships and external infrastructure.

• Strong balance sheet: $21 million cash, no debt, clean capital structure, and low annual cash burn.

Clinical programs and recent data

• CAR-T therapy for ovarian cancer shows early efficacy and unique dual mechanism targeting tumor cells and vasculature.

• Intraperitoneal delivery reduces systemic side effects and enhances local efficacy.

• One terminal patient survived 20 months post-treatment, exceeding expectations.

• Breast cancer vaccine induces strong immune response, with no significant side effects beyond injection site irritation.

• Combination with Keytruda is safe and maintains T-cell response; phase II trial planned for next year.

Market opportunity and commercialization

• Both CAR-T and vaccine programs target large, non-rare cancer populations.

• Long-term plan is to partner with major pharma for commercialization, avoiding in-house manufacturing and distribution.

• CAR-T may reach approval faster due to smaller required trial sizes for terminal patients.

• Vaccine approval for prophylactic use will take longer, but monetization via pharma partnerships is planned before full approval.

• Already receiving inbound interest from potential partners.